Delivery Order SPE2DR25D3501-SPE2DR26FL8PB
- Not listed
- The Defense Logistics Agency awarded a $10,518.48 firm fixed price delivery order to AmerisourceBergen Drug Corp for 400 mg vials of Benlysta, a biologic medication used to treat systemic lupus erythematosus and lupus nephritis. The order was competitively awarded without set-aside designation and is scheduled for completion by September 23, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this delivery order from its corporate office location. This delivery...
- The Defense Logistics Agency awarded a $34,196.40 delivery order to AmerisourceBergen Drug Corp for 400 mg vials of Benlysta, a therapeutic pharmaceutical used primarily in the treatment of systemic lupus erythematosus. This firm fixed-price delivery order, awarded on September 22, 2025, with an ultimate completion date of October 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award carries no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $6,165.34 to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector, with an ultimate completion date of October 16, 2025. This non-competitive, firm fixed-price delivery order represents a single purchase of this biologic medication used primarily in the treatment of systemic lupus erythematosus. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Benlysta 200 mg/ml auto-injector, a specialty pharmaceutical product used in the treatment of systemic lupus erythematosus. This non-set-aside, competitively awarded contract carries a ceiling value of $6,165.34 and is classified as a firm fixed price delivery order with an ultimate completion date of September 26, 2025. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector units on September 11, 2025, with an ultimate completion date of October 2, 2025. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $3,082.67 and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Benlysta is a biologic medication used to treat systemic lupus erythematosus and lupus nephritis,...
- The Defense Logistics Agency awarded a $22,357.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 400 mg vials of Benlysta, a monoclonal antibody treatment used for systemic lupus erythematosus. This non-competitive delivery order, issued on September 10, 2025, must be completed by October 1, 2025. The pharmaceutical supply will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters and a key...
- The Defense Logistics Agency awarded a delivery order valued at $6,165.34 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector, a biologic immunosuppressant used to treat systemic lupus erythematosus. This firm fixed-price delivery order, awarded August 18, 2025, with completion by September 9, 2025, represents a competitive procurement with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,987.78 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on May 13, 2025, with completion expected by June 4, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta is a biologic medication used to treat systemic lupus erythematosus and lupus nephritis, representing a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/ml auto-injector, a biologic immunosuppressant medication used to treat systemic lupus erythematosus. This firm fixed-price delivery order, valued at $6,165.34, was competitively awarded without set-aside provisions and carries an ultimate completion date of September 5, 2025. The contract will be fulfilled at AmerisourceBergen Drug Corp's corporate office location in...
- The Defense Logistics Agency awarded a $10,258.92 delivery order to AmerisourceBergen Drug Corp for 400 mg vials of Benlysta, a biologic medication used to treat systemic lupus erythematosus and other autoimmune conditions. This firm fixed-price delivery order, issued on April 24, 2025, with an ultimate completion date of May 15, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively...
- SPE2DR25D3501Indefinite Delivery Contract
- SPE2DR25D3501-SPE2DR26FL8PBDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 13, 2025, for the supply of Benlysta 120 mg vials, a biologic medication used to treat systemic lupus erythematosus. This firm fixed-price delivery order carries a ceiling value of $4,162.80 and is scheduled for completion by December 5, 2025. The contract represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as the primary pharmaceutical supply vehicle for federal military and healthcare systems. As a major pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's federal contracting history demonstrates consistent capability to fulfill competitive pharmaceutical procurement requirements through both small-value and substantial orders.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 11/13/25 |